Supplier Related Products Identification Chemical Properties Safety Data Hazard Information Questions And Answer
WebSite >  CAS DataBase List  > 95058-81-4

95058-81-4

Supplier Related Products Identification Chemical Properties Safety Data Hazard Information Questions And Answer

Product Image

Identification

Name
Gemcitabine
CAS
95058-81-4
Synonyms
2'-DEOXY-2',2'-DIFLUOROCYTIDINE
4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
GEMCITABINE
GEMCITABINE HCL USP
2'-Deoxy-2',2'-difluro cytidine Hydrochloride
2'-Deoxy-2',2'-difluoro-D-cytidine
2''-DEOXY-2'',2''-DIFLUOROCYTIDINE(GEMCITABINE)
2',2'-Difluorodeoxycytidine
Cytidine, 2'-deoxy-2',2'-difluoro-
gemicitabine
NSC 613327
gencitabine base
2',2'-Difluorodeoxycytidine (Gemcitabine base)
GEMCITABINE (2''-DEOXY-2'', 2''-DIFLUOROCYTIDINE)
LY-18011
Molecular Formula
C9H11F2N3O4
MDL Number
MFCD00869720
Molecular Weight
263.2
MOL File
95058-81-4.mol

Chemical Properties

mp 
168,64 C
CAS DataBase Reference
95058-81-4(CAS DataBase Reference)

Safety Data

Hazard Codes 
Xn,Xi
Risk Statements 
R21:Harmful in contact with skin.
R36/38:Irritating to eyes and skin .
R62:Possible risk of impaired fertility.
R63:Possible risk of harm to the unborn child.
Safety Statements 
S25:Avoid contact with eyes .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36/37:Wear suitable protective clothing and gloves .
S53:Avoid exposure-obtain special instruction before use .
HS Code 
29349900
Hazardous Substances Data
95058-81-4(Hazardous Substances Data)

Hazard Information

Hazard
Human systemic effects

Questions And Answer

Description
Gemcitabine (2’,2’-difluorodeoxycytidine; dFdCyd) is a novel deoxycytidine analogue with both structural and metabolic similarities to cytarabine. It has a broad spectrum of antitumor activity in preclinical murine leukemia and solid tumor models. This drug requires intracellular phosphorylation that results in the accumulation of difluorodeoxycytidine triphosphate (dFdCTP). The dFdCTP competes with deoxycytidine triphosphate (dCTP) for incorporation into DNA, which in turn inhibits DNA synthesis and terminates DNA chain elongation. In addition, this drug reduces intracellular deoxynucleoside triphosphate pools, presumably through the inhibition of ribonucleotide reductase.
Gemcitabine is used alone or with other treatments/medications to treat certain types of cancer (including breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, bladder cancer, bone cancer, Ewing’s sarcoma, mesenchymal chondrosarcoma osteosarcoma, dedifferentiated chondrosarcoma, head and neck cancers-cancer of the nasopharynx, hepatobiliary cancers including gallbladder cancer, Hodgkin lymphoma, kidney cancer, malignant pleural mesothelioma, non Hodgkin lymphoma, non-melanoma skin cancer – dermatofibrosarcoma protuberans (DFSP), occult primary, small cell lung cancer, soft tissue sarcoma, testicular cancer, thymic malignancies, uterine malignancies). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. One commercial product of gemcitabine is Gemzar, which is supplied in a sterile form for intravenous use only.
References
[1] H. A. Burris, M. J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg, M. R. Modiano, M. C. Cripps, R. K. Portenoy, A. M. Storniolo, P. Tarassoff, R. Nelson, F. A. Dorr, C. D. Stephens, D. D. Von Hoff (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, 15, 2403-2413
[2] http://www.webmd.com/drugs/2/drug-13451/gemcitabine-intravenous/details
SupplierMore